Toth Financial Advisory Corp Has $42,000 Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Toth Financial Advisory Corp trimmed its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 96.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,150 shares of the biopharmaceutical company’s stock after selling 59,200 shares during the period. Toth Financial Advisory Corp’s holdings in Catalyst Pharmaceuticals were worth $42,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Huntington National Bank lifted its position in shares of Catalyst Pharmaceuticals by 105.0% during the 2nd quarter. Huntington National Bank now owns 1,433 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 734 shares during the last quarter. Dakota Community Bank & Trust NA bought a new position in Catalyst Pharmaceuticals in the 2nd quarter worth approximately $81,000. Quarry LP lifted its holdings in shares of Catalyst Pharmaceuticals by 60.0% during the first quarter. Quarry LP now owns 8,000 shares of the biopharmaceutical company’s stock worth $194,000 after buying an additional 3,000 shares during the last quarter. GW Henssler & Associates Ltd. bought a new stake in shares of Catalyst Pharmaceuticals in the first quarter valued at approximately $206,000. Finally, Financiere des Professionnels Fonds d investissement inc. acquired a new stake in shares of Catalyst Pharmaceuticals in the second quarter worth $206,000. 79.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on CPRX shares. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. Citigroup upped their price objective on shares of Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Wednesday. Finally, Oppenheimer restated an “outperform” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, November 7th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $32.67.

Insiders Place Their Bets

In related news, insider Carmen Jeffrey Del sold 10,983 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $23.33, for a total transaction of $256,233.39. Following the completion of the transaction, the insider directly owned 3,962 shares of the company’s stock, valued at $92,433.46. This trade represents a 73.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Molly Harper sold 26,746 shares of Catalyst Pharmaceuticals stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $23.25, for a total transaction of $621,844.50. Following the transaction, the director directly owned 2,360 shares of the company’s stock, valued at $54,870. This represents a 91.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 10.40% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Trading Up 0.3%

NASDAQ CPRX opened at $23.74 on Monday. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $26.58. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of 13.80, a PEG ratio of 0.84 and a beta of 0.69. The stock’s 50 day moving average is $22.31 and its two-hundred day moving average is $21.57.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Monday, September 25th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter. The business had revenue of $53.11 million during the quarter. Catalyst Pharmaceuticals had a return on equity of 39.24% and a net margin of 37.63%. On average, analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.9 earnings per share for the current year.

Catalyst Pharmaceuticals declared that its Board of Directors has approved a stock repurchase program on Wednesday, October 1st that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the biopharmaceutical company to repurchase up to 8.3% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).